Recombinetics
St. Paul, US · 1 known investors
Recombinetics develops gene-edited animals, offering custom gene-edited swine models for translational preclinical and biomedical research, including reporter and cancer models. It also applies gene editing to food animals to improve animal health, welfare, and sustainability in agriculture.
Founders & leadership
SC
Scott C. Fahrenkrug, Ph.D.Founder
JC
John CameronExecutive
DA
David AberleExecutive
JZ
Justin ZenankoExecutive
TL
Tammy Lee StanochExecutive
MA
Mitchell Abramhamsen, Ph.D.Executive
PB
Perry B. Hacket, Ph.D.Named on SEC filing
PB
Perry B. Hackett, Ph.D.Named on SEC filing
WM
William McKnight, Jr.Named on SEC filing
CH
Cliff HoffmanNamed on SEC filing
MW
Mark Walton, Ph.D.Named on SEC filing
SC
Scott C. FahrenkrugNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$54.4M disclosed across 6 rounds · 2014–2018
▶$7.7MraisedFeb 2019 · 11 investors · BiotechnologyRule 506(b)
▶$7.7MraisedFeb 2019 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Justin ZenankoDirector
- Scott C. Fahrenkrug, Ph.D.Director, Promoter
- John BurtisExecutive Officer
- Tammy LeeExecutive Officer
- Mitchell Abrahamsen, Ph.D.Executive Officer
- Daniel F. Carlson, Ph.D.Executive Officer
- Bill FarrellDirector
- Jerry ArndtDirector
- Jim KilmanDirector
- Peter HajasDirector
- Scott RathgaberDirector
- David AberleExecutive Officer
- Offering amount
- $27.6M
- Amount sold
- $7.7M
- First sale
- Oct 2016
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
▶$33.5MraisedSep 2018 · 14 investors · BiotechnologyRule 506(b)
▶$33.5MraisedSep 2018 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John CameronExecutive Officer
- Jerry ArndtDirector
- Jim KilmanDirector
- Bill FarrellDirector
- Peter HajasDirector
- Daniel F. Carlson, Ph.D.Executive Officer
- David AberleExecutive Officer
- Mitchell Abramhamsen, Ph.D.Executive Officer
- John BurtisExecutive Officer
- Tammy LeeExecutive Officer
- Justin ZenankoExecutive Officer, Director
- Scott C. Fahrenkrug, Ph.D.Director, Promoter
- Offering amount
- $33.5M
- Amount sold
- $33.5M
- First sale
- Aug 2018
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
▶$6.4MraisedMar 2018 · 47 investors · BiotechnologyRule 506(b)
▶$6.4MraisedMar 2018 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark Kroll, Ph.D.Director
- John CameronExecutive Officer
- David AberleExecutive Officer
- Peter HajasDirector
- Scott C. Fahrenkrug, Ph.D.Director, Promoter
- Justin ZenankoExecutive Officer
- Tammy Lee StanochExecutive Officer
- Jim KilmanDirector
- Wendell KingDirector
- Robert SwitzDirector
- Mitchell Abramhamsen, Ph.D.Executive Officer, Director
- Perry B. Hacket, Ph.D.Director
- John BurtisExecutive Officer
- Daniel F. Carlson, Ph.D.Executive Officer
- Offering amount
- $18.1M
- Amount sold
- $6.4M
- Sales commissions
- $907.5K
- Placement agents
- Van Clemens & Co. Incorporated
- First sale
- Sep 2017
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
▶$630KraisedAug 2016 · 7 investors · BiotechnologyRule 506(b)
▶$630KraisedAug 2016 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Justin ZenankoExecutive Officer
- Robert SwitzDirector
- Perry B. Hackett, Ph.D.Director
- Mitchell Abrahamsen, Ph.D.Director
- Wendell KingDirector
- John F. CameronExecutive Officer
- Tammy Lee StanochExecutive Officer
- Ian R. FriendlyExecutive Officer
- Mark Kroll, Ph.D.Director
- Paul Olson, Ed.D.Director
- Scott C. Fahrenkrug, Ph.D.Executive Officer, Director
- Offering amount
- $3.7M
- Amount sold
- $630K
- Sales commissions
- $184.4K
- First sale
- Jul 2016
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
▶$5.7MraisedJul 2016 · 89 investors · BiotechnologyRule 506(b)
▶$5.7MraisedJul 2016 · 89 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John F. CameronExecutive Officer
- Tammy Lee StanockExecutive Officer
- Perry B. Hackett, Ph.D.Executive Officer
- Justin ZenankoExecutive Officer
- Paul OlsonDirector
- Ian R. FriendlyExecutive Officer
- Robert SwitzDirector
- Scott C. FahrenkrugExecutive Officer, Director
- Mark Kroll, Ph.D.Director
- Wendell KingDirector
- Mitch AbrahamsenDirector
- Offering amount
- $10M
- Amount sold
- $5.7M
- Sales commissions
- $500K
- Proceeds to insiders
- $1.1M
- First sale
- Jun 2015
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
▶$540.8KraisedOct 2014 · 25 investors · BiotechnologyRule 506(b)
▶$540.8KraisedOct 2014 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Perry B. Hackett, Ph.D.Executive Officer
- William McKnight, Jr.Director
- Cliff HoffmanDirector
- Justin ZenankoExecutive Officer
- Mark Walton, Ph.D.Executive Officer
- Scott C. FahrenkrugExecutive Officer, Director
- Greg MelsenDirector
- Douglas KeethDirector
- Offering amount
- $3M
- Amount sold
- $540.8K
- Sales commissions
- $100K
- Proceeds to insiders
- $153K
- Placement agents
- Van Clemens & Co. Incorporated
- First sale
- Aug 2014
- Incorporated
- Corporation, Minnesota
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 19 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $342.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $399K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $224.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $398.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $398.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $394.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $358.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $355.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $347.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $376.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $301.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $375.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $352.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $232.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2011 | $318.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Recombinetics do?
- Recombinetics develops gene-edited animals, offering custom gene-edited swine models for translational preclinical and biomedical research, including reporter and cancer models. It also applies gene editing to food animals to improve animal health, welfare, and sustainability in agriculture.
- Who founded Recombinetics?
- Recombinetics was founded by Scott C. Fahrenkrug, Ph.D..
- Who are Recombinetics's investors?
- Recombinetics's investors include Newlin Ventures.
- How much funding has Recombinetics raised?
- Recombinetics has disclosed $54.4M raised across 6 rounds.
- Where is Recombinetics headquartered?
- Recombinetics is headquartered in St. Paul, US.